# Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

> **NCT07210047** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **HuniLife Biotechnology, Inc.** · enrollment: 21 (estimated)

## Conditions studied

- Multiple Myeloma Refractory

## Interventions

- **BIOLOGICAL:** HuL001-10 mg/kg
- **BIOLOGICAL:** HuL001-15 mg/kg
- **DRUG:** Lenalidomide and Dexamethasone

## Key facts

- **NCT ID:** NCT07210047
- **Lead sponsor:** HuniLife Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-08-18
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-01-31
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07210047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07210047, "Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT07210047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*